1.21
-0.15 (-11.03%)
| Penutupan Terdahulu | 1.36 |
| Buka | 1.36 |
| Jumlah Dagangan | 6,044,422 |
| Purata Dagangan (3B) | 3,347,793 |
| Modal Pasaran | 321,092,864 |
| Harga / Pendapatan (P/E Ke hadapan) | 29.59 |
| Harga / Jualan (P/S) | 1.29 |
| Harga / Buku (P/B) | 9.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Keuntungan | -24.51% |
| Margin Operasi (TTM) | 23.85% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 75.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 795.72% |
| Nisbah Semasa (MRQ) | 2.23 |
| Aliran Tunai Operasi (OCF TTM) | -34.81 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 12.96 M |
| Pulangan Atas Aset (ROA TTM) | -4.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Akebia Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.88 |
|
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.59% |
| % Dimiliki oleh Institusi | 38.96% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 6.00 (HC Wainwright & Co., 395.87%) | Beli |
| Median | 4.00 (230.58%) | |
| Rendah | 4.00 (BTIG, 230.58%) | Beli |
| 4.00 (Piper Sandler, 230.58%) | Beli | |
| Purata | 4.67 (285.95%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 1.33 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 25 Feb 2026 | 4.00 (230.58%) | Beli | 1.21 |
| HC Wainwright & Co. | 06 Feb 2026 | 6.00 (395.87%) | Beli | 1.39 |
| Piper Sandler | 06 Feb 2026 | 4.00 (230.58%) | Beli | 1.39 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 02 Feb 2026 | Pengumuman | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Pengumuman | Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook |
| 06 Jan 2026 | Pengumuman | Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) |
| 05 Jan 2026 | Pengumuman | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |